OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States and internationally. Its products include OraQuick ADVANCE HIV-1/2, a point-of-care qualitative test for antibodies to the Human Immunodeficiency Virus (HIV) Type 1 and 2; OraQuick HCV, a point-of-care qualitative test for antibodies to the hepatitis C virus; OraSure QuickFlu Rapid Flu A&B Test, a point-of-care qualitative test for antibodies to influenza Types A and B, including H1N1 infections; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1 in an oral fluid sample; and Intercept, an oral fluid collection device for oral fluid drugs of abuse testing in a laboratory setting. The company’s products also comprise cryosurgical systems for the removal of common and plantar warts, and other benign skin lesions; Oragene DX, OMNIgene DISCOVER, ORAcollect, and Oragene•DNA, which are non-invasive systems for the collection, stabilization, transportation, and storage of human DNA from saliva; OMNIgene•DISCOVER, a non-invasive all-in-one system for the collection, stabilization, transportation, and storage of microbial DNA from saliva; and Performagene LIVESTOCK and Oragene ANIMAL systems for the collection, stabilization, transportation, and storage of livestock DNA from nasal samples. In addition, it sells immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.